<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525967</url>
  </required_header>
  <id_info>
    <org_study_id>217/2005</org_study_id>
    <nct_id>NCT00525967</nct_id>
  </id_info>
  <brief_title>Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain</brief_title>
  <official_title>Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain: A Randomized, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral methadone plus acetaminophen can
      substitute morphine in the treatment of cancer pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opioids are the mainstay of moderate-to-severe cancer pain management. Although morphine is
      the most commonly used, methadone has some advantages such as higher potency, lower cost and
      longer administration intervals. To minimize the time necessary to achieve the equianalgesic
      effect after a switching from morphine to methadone, acetaminophen was added in the
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">October 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity and time to equianalgesic effect</measure>
    <time_frame>within the first 7 days after switching</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of nausea, vomiting, obstipation, xerostomia and drowsiness</measure>
    <time_frame>within the first 7 days of switching</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methadone plus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methadone plus Acetaminophen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone plus Acetaminophen or Placebo</intervention_name>
    <description>Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of cancer pain

          -  Regular use of oral Morphine

        Exclusion Criteria:

          -  Use of Acetaminophen in the last 48 hours

          -  Renal or Hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel IG Cubero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Auro del Giglio</last_name>
    <role>Study Director</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel IG Cubero, MD</last_name>
    <phone>55-11-81799103</phone>
    <email>danielcubero@uol.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Disciplina de Oncologia, Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auro del Giglio, Professor</last_name>
      <phone>55-11-49935491</phone>
      <email>sandrabr@netpoint.com.br</email>
    </contact>
    <investigator>
      <last_name>Daniel IG Cubero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.palliativedrugs.com</url>
    <description>Newsletter, March 2004</description>
  </link>
  <results_reference>
    <citation>Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998 Oct;16(10):3216-21.</citation>
    <PMID>9779694</PMID>
  </results_reference>
  <results_reference>
    <citation>Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001 Jun 1;19(11):2898-904.</citation>
    <PMID>11387363</PMID>
  </results_reference>
  <results_reference>
    <citation>Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999 Oct;17(10):3307-12.</citation>
    <PMID>10506634</PMID>
  </results_reference>
  <results_reference>
    <citation>Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol. 2005 Aug 1;23(22):5229-34.</citation>
    <PMID>16051965</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004 Jan 1;22(1):185-92.</citation>
    <PMID>14701781</PMID>
  </results_reference>
  <results_reference>
    <citation>Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol. 2004 Aug 15;22(16):3389-94.</citation>
    <PMID>15310785</PMID>
  </results_reference>
  <results_reference>
    <citation>Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998 Nov;16(11):3656-61.</citation>
    <PMID>9817288</PMID>
  </results_reference>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <last_update_submitted>September 5, 2007</last_update_submitted>
  <last_update_submitted_qc>September 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2007</last_update_posted>
  <keyword>Cancer Pain</keyword>
  <keyword>Methadone</keyword>
  <keyword>Morphine</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Palliative Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 10, 2013</submitted>
    <returned>April 22, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

